Learning Objectives Describe applicable results of important - - PowerPoint PPT Presentation

learning objectives
SMART_READER_LITE
LIVE PREVIEW

Learning Objectives Describe applicable results of important - - PowerPoint PPT Presentation

Learning Objectives Describe applicable results of important histology-specific clinical trials and put into clinical context Identify investigational therapeutic regimens that would be alternatives to standard of care approaches


slide-1
SLIDE 1

Learning Objectives

  • Describe applicable results of important

histology-specific clinical trials and put into clinical context

  • Identify investigational therapeutic

regimens that would be alternatives to standard of care approaches

  • Evaluate current clinical practice

approaches and applications to each specific patient and suggest alternative radiology, pathology, and clinical practices

slide-2
SLIDE 2

Accreditation and Credit Statement

Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Mayo Clinic College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

slide-3
SLIDE 3

DISCLOSURE

Conference Directors / Planning Committee

No Relevant Financial Relationship(s)

Thomas M. Habermann, M.D. Rebecca L. King, M.D. Thomas E. Witzig, M.D.

Off Label/Investigational Usage

Any off-label or investigational use of a drug of device should be announced to others if discussed.

slide-4
SLIDE 4

The following are off-label or investigational use and may come up during discussion:

Pharmacylics, Jansen Gilead Sciences Celgene Seattle Genetics Novartis, Kite Merck Bristol-Meyers Squibb Novartis Millenium/Takeda AbbVie/Genentech/Roche AbbVie/Genetech/Roche Takeda Ibrutinib Idelalisib Lenalidomide Brentuximab vedotin CAR T-cells Pembrulizumab Novolumab Everolimus Alisertib Venetoclax Ibrutinib Bortezomib